Phone: +44 (0)1223 746438 Highlights 1) Objective T2WI and DWI helped improve cancer yield for equivocal (PI-RADS 3) lesions 2) Biopsy recommendation improved PPV to 32% for GS 7-10 and 61% for any cancer 3) No-biopsy recommended had equivalent NPV to a negative MRI (PI-RADS 1-2) at 92% 4) The criteria-based score system could potentially avoid 48% of biopsies in the cohort
Introduction
Multiparametric prostate MRI (mpMRI) has become established in the diagnostic pathway of men with prostate cancer [1] [2] [3] and is now increasingly used in the prebiopsy setting to allow selection of men with significant cancer for biopsy, while avoiding biopsy and unnecessary treatment in men without an MRI lesion [4, 5] .
The recently updated Prostate Imaging-Reporting and Data System (PI-RADS) guidelines are aimed at standardizing MRI acquisition and interpretation using a 5-point scoring system [6, 7] . However, when MRI is being used to guide the clinical decision making process either in the context of a previous negative biopsy, or in biopsy naïve patients, this 5-point scale has to be translated into a binary decision of whether to biopsy or not. A PI-RADS score of 1-2 is considered a "negative" MRI, and has a >90% negative predictive value (NPV) for significant disease [8] [9] , thus biopsy can be reasonably avoided. Conversely, a PI-RADS 4-5 lesion is of high probability and targeted biopsy is warranted. An intermediate PI-RADS 3 lesion, however, straddles this decision making process, and biopsy in this case is under debate [10] [11] [12] . The overall detection of cancer in indeterminate lesions has been shown to vary from 6.5% -60% for any cancer and 4.1% -21% for significant cancer [10,13 -16] .
This needs to be considered in the context of a "miss rate" of around 10% for a PIRADS score of 1-2. Importantly, detection rates have been shown to be higher in the peripheral zone [14] and as high as 40% in the context of a second-biopsy population [15] , suggesting some PI-RADS 3 lesions deserve biopsy, whereas others could be safely deferred. Informing management of such lesions is particularly relevant given the reported prevalence of indeterminate of 20.5-26.3% using earlier Likert-based systems [10, [16] [17] [18] is predicted to increase with a switch to using the PI-RADS-version 2 reporting system [19] .
The aim of this study therefore was to evaluate if equivocal PI-RADS 3 lesions on mpMRI of the prostate can be further differentiated using pre-defined T2-and diffusion-weighted imaging (DWI) criteria, in order to aid in the biopsy decision process.
Materials and Methods

Study population
This single-institution retrospective study was part of an evaluation of transperineal prostate biopsies with the need for informed consent for data analysis waived by the local ethics committee. From January 2013 to April 2016, 155 consecutive patients with a dominant (index) lesion considered to be equivocal on mpMRI (PI-RADS 3) underwent transperineal prostate biopsies at our tertiary center. 4 patients were excluded due to hip replacements, 8 patients were excluded as their scans were performed on a 1.5T MRI scanner. Out of the remaining 143 patients, 35 had no previous prostate biopsies, 82 had previous negative systematic transrectal ultrasound (TRUS)-guided biopsies, and 26 were due for follow-up biopsy under active surveillance for Gleason score 6 cancer. The Standards of Reporting for MRItargeted Biopsy Studies (START) were used to describe the study population, the conduct and reporting of the MRI, and the conduct of the biopsy and the Standards of Reporting of Diagnostic Accuracy (STARD) were used to describe and discuss the results [20, 21] .
Magnetic resonance imaging
All patients underwent MRI on a 3-T scanner (HDx, GE Healthcare) using a 16-32 channel phased-array body coil. The MRI protocol included axial T1-weighted fast spin-echo (FSE) images of the pelvis and high-resolution T2-weighted fast recovery FSE images of the prostate in axial, sagittal, and coronal planes. T1-weighted imaging parameters were as follows: TR/TE, 561/11; flip angle, 70°; FOV, 24 × 24 cm; resolution 1.1 x 1.0. T2-weighted imaging parameters were as follows: TR/TE, 4273/102; FOV, 22 × 22 cm; resolution 0.8 x 0.7; 1.5 signal averages. Axial DWI was performed using a dual spin-echo planar imaging pulse sequence (TR/TE, 3775/70; FOV, 28 × 28 cm; resolution 2.2 x 2.2). A parallel imaging with array spatial sensitivity encoding technique was used with an acceleration factor of 2 to reduce image distortion, with 6 signal averages. The slice thickness for the axial T2- 
Image analysis
All mpMRI images were prospectively read at our center by one of two subspecialist body radiologists experienced in reading prostate MRI. T2WI and DWI sequences were prospectively evaluated using a Likert scale of tumor probability, based on the Prostate Imaging Reporting and Data System (PI-RADS v1) structured scoring criteria developed by the European Society of Urogenital Radiology (ESUR) [22] and a final score was defined by combining all scores for T2WI and DWI sequences as recommended in PI-RADS version 2 [23] . Equivocal "Likert 3" was taken to be equivalent to PI-RADS 3 and only the equivocal lesions were further analysed for this study. Two radiologists with 2 years (approximately 200 cases read) and 7 years (over 2,000 cases) years of experience performed a blinded retrospective second-read of each. In each case the readers were provided with the location of the lesion originally reported according to the PI-RADS sector map, in order to ensure the same lesion was re-assessed. Objective imaging criteria derived from PI-RADS descriptors were used to assess each lesion, along with topographical information such as anterior location of transition zone lesions or radial/parallel orientation of peripheral zone lesions [24] [25] [26] ; table 1. The location of transition zone lesions was identified according to the sector map as originally reported and therefore interreader agreement was not assessed for this criterion. Finally, readers were asked to give a subjective binary recommendation whether or not to biopsy.
Biopsy
The Biopsee TM transperineal MRI/TRUS fusion biopsy system version 1 or 2 (Medcom, Darmstadt, Germany) was used for all biopsies. All patients had 18-24 systematic biopsies taken according to the Ginsburg protocol, using a spring-loaded biopsy gun with an 18 gauge needle [27] . 2 target biopsy cores were taken from each lesion before the systematic biopsies. In the systematic biopsy, 2 biopsy cores were sampled from each of 12 sectors, starting with the anterior sectors. All procedures were undertaken by 1 of 2 urologists with several years' experience of transperineal biopsy using the Biopsee TM MRI/TRUS fusion biopsy system.
Histopathology
All biopsies were reported by a specialist uropathologist and were reviewed a second time, by another uropathologist, prior to discussion at a multidisciplinary Table 5 .
Peripheral zone lesions
For peripheral zone (PZ) lesions, significant differences in cancer detection were found using the imaging criteria shape, DWI, and ADC. After Bonferroni-Holm correction for multiple comparisons, the criteria ADC and shape remained statistically significant for detection of any cancer, with ADC also being significant for detection of significant cancer. For wedge-shaped/geographical shape, PPV for detecting any cancer in the target area were 0.26±0.13 compared to 0.69±0.23 for round shape (p=0.0055, Kappa=0.466, CI 0.253 to 0.680). PPV was also higher for detection of GS 7-10 but the difference was not statistically significant (p>0.05). For a mildly reduced ADC, PPV for detecting any cancer in the target area was significantly lower for mild at 0.21±0.12 compared to strong restriction at 0.81±0.19 (p=0.0001, Kappa=0.033, CI -0.017 to 0.083) and also lower for significant cancer, PPV 0.07±0.08 vs. 0.56±0.24, respectively (p=0.0002).
Transition zone lesions
For transition zone (TZ) lesions, significant differences in cancer detection were found using the imaging criteria location, shape, border, homogeneity and ADC.
After Bonferroni-Holm correction for multiple comparisons, the criteria location, border, and ADC remained statistically significant for detection of any cancer while the criterium border was also significant for detection of significant cancer. For mid/posterior location, the PPV for any cancer in the target area was significantly lower at 0.31±0.14 compared to 0.63±0.15 for an anterior location (p=0.0048). 
Biopsy Recommendation
When asked to make a subjective biopsy recommendation, agreement between the two readers was observed in 62.2% of cases (89/143, Kappa=0.263, 95% CI 0.118 to 0.407). PPVs for detecting any cancer in the target area for the experienced reader were 0.21±0.10 for "defer biopsy" vs. 0.61±0.11 (p=0.0001) for "biopsy recommended" (Figures 1-4) , with PPVs for significant cancer of 0.08±0.07 vs. 0.32±0.10, respectively (p=0.0003). Even for a less experienced reader, this effect was significant, although not as pronounced, with a PPV for detecting any cancer of 0.35±0.10 for "defer biopsy" vs. 0.57±0.14 for "biopsy recommended" (p=0.0133) and PPV for significant cancer of 0.14±0.07 vs. 0.35±0.13 (p=0.0050), respectively ( Figure 5 ).
Discussion
Our study shows that re-evaluation of equivocal MRI lesions by an experienced uroradiologist, using only topographical, T2WI, and DWI and assessing set imaging criteria, improved diagnostic accuracy. Adding a subjective recommendation of whether or not to biopsy a lesion improved the cancer yield to 32% for GS 7-10 cancers and justified the "deserves biopsy" recommendation. Conversely the NPV of 0.92 for "avoid biopsy" lesions is equivalent to the NPV of a negative MRI (PI-RADS 1-2), which is effectively the reference standard for deferring biopsy. Even for a less experienced reader, this effect was found, although not as pronounced.
The overall PPV for an equivocal lesion was 43% for any cancer and 21% significant cancer, suggesting that the cancer detection rate in this group is too high to completely avoid biopsy. Rosenkrantz et al found detection rates of PI-RADS 3 lesions to be as high as 40% for any cancer and 14.5% for GS 7-10 in the context of a second-biopsy population, compared to lower detection rates in a biopsy-naïve population [15] . This needs to be taken into account when analyzing a mixed study population like ours and especially when undertaking a biopsy decision for an individual patient. Liddell et al. showed cancer detection rates to be generally lower at 6.5% in the PZ and 2.2% in the TZ [14] , conversely we found higher detection rates in the TZ (48%) compared to PZ (38%), which may again reflect differences in the study populations.
A subjective biopsy recommendation requires reading experience and continuous feedback from biopsy results, therefore we also evaluated which individual imaging criteria are most useful to risk stratify equivocal prostate lesions. We found that for PZ lesions, the presence of round shape and low ADC significantly improved detection of any cancer, with a low ADC value yielding significantly higher rates of significant cancer. This is expected as DWI is the dominant sequence in the PZ, and shape is a key component of the scoring system in the PZ, particularly distinguishing a rounded (PI-RADS 4-5) versus ill-defined/geographical shape (PI-RADS 2).
Differentiation of other criteria on T2-weighted images such as location, border, T2 signal intensity, homogeneity and high DWI did not significantly improve cancer yield. For transition zone lesions, anterior location, ill-defined border, and low ADC yielded higher rates of cancer, with ill-defined borders also resulting in significantly higher rates of significant cancer detection. Again this is supportive of the PI-RADS system, where T2WI dominates and morphological features of a pseudocapsule or homogeneous appearance reflect PI-RADS category 2 or 4 lesions, respectively. Interestingly, the use of the topographical information of anterior location helped further risk stratify TZ lesions, this is supportive of previous work [24] and could be considered in future iterations of the PI-RADS scoring system. Other criteria such as T2 signal intensity and DWI did not improve GS 7-10 cancer yield for transition zone lesions, the latter reflecting the secondary role played by DWI in the TZ. Interreader agreement for both DWI and ADC was noted to be lower than for other imaging criteria, which may reflect the selection bias of indeterminate PIRADS-3 lesions, i.e. cases with no or marked restricted diffusion are unlikely to be in the cohort. The results, however, lend further support to suggestions that future versions of PI-RADS state quantitative cut-offs or to use ADC ratios to help reduce subjectivity [26, 29] . It should be noted that all lesions retrospectively analysed in this study were originally categorized as PI-RADS 3 and therefore likely exhibited the assessed criteria to a lower degree than lesions directly categorized as negative (PI-RADS 2) or suspicious (PI-RADS 4-5).
A strength of our study is the use of a targeted and a 24-core systematic transperineal biopsy approach as the reference standard. Limitations of this study are its retrospective analysis and the relatively small study population. As with any biopsy technique there is the potential for sampling error, for example leading to false negative results, however this is expected to be reduced with targeted compared to systematic biopsy. Although a prostatectomy cohort would offer more definitive histology, this would not include cases negative for cancer, and patients with PI-RADS 3 lesions are less likely to undergo radical treatment. All lesions were prospectively called using the criteria and the Likert descriptor of 1-5 that was incorporated in PI-RADS version 1, wherein "Likert 3" there was taken to be equivalent to PI-RADS 3. For the retrospective analysis, the criteria definitions of PI-RADS version 2 along with topographical information such as anterior location of transition zone lesions or radial/parallel orientation of peripheral zone lesions were used. The initial classification as PI-RADS 3 may not have been correct in all cases, highlighting the value of double reading not only in a scientific but also a clinical setting. In addition, some lesions classified as intermediate probability using criteria from version 1 of the guidelines may be considered to be of PI-RADS 4 category using version 2 (Figure 4.) . In this study, all initially intermediate lesions were reread by an intermediately experienced (7 years) and a beginner (2 years) reader which again reflects clinical practice in many centres, few of which can provide a reader with more than 10 years of experience. This slightly limits the generalizability of our findings as reader studies addressing different levels of experience should ideally include 2 readers of each experience level. Dynamic contrast enhanced imaging was not used in all cases and therefore not evaluated, however, there is conflicting evidence to whether DCE is needed for prostate imaging, with some studies demonstrating a small benefit in the peripheral zone [30, 31] , whilst others have countered that inter-reader agreement for DCE is weak, especially in the peripheral zone [32] and added value is limited [33] . Recently, biparametric prostate MRI was found to offer a diagnostic accuracy and cancer detection rate equivalent to that of conventional full multiparametric contrastenhanced MR imaging protocols [34] . Our results offer an alternative to DCE by establishing that equivocal lesions, particularly in the peripheral zone, can be further differentiated by in-depth analysis of topography, T2WI, and DWI and a subjective biopsy recommendation given by an experienced radiologist.
Conclusions
Identification of certain objective imaging criteria as well as a subjective biopsy recommendation from an experienced radiologist can help to increase the predictive value of equivocal prostate lesions and inform the decision making process of whether or not to biopsy. 
